Skip to main content

approvalsWatch: Oncology 290116

US FDA Approvals

Eribulin mesylate
The chemotherapeutic drug eribulin mesylate has been approved by the FDA under its priority review programme and is for patients with unresectable or metastatic liposarcoma. The agent is indicated for patients who have previously received anthracycline-based chemotherapy. 

European Medicines Agency Approvals

Following accelerated assessment, the EMA’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of a marketing authorisation for elotuzumab for adult patients with multiple myeloma who have received one or more previous treatment. The monoclonal antibody targets SLAMF7 (signaling lymphocyte activation molecule family member 7) and is intended to be administered together with lenalidomide and dexamethasone.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits